Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer

Authors: Brandon M Barney, Ivy A Petersen, Sean C Dowdy, Jamie N Bakkum-Gamez, Kristi A Klein, Michael G Haddock

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Background

To report outcomes in women with locally recurrent or advanced cervical cancer who received intraoperative electron beam radiotherapy (IOERT) as a component of therapy.

Methods

From 1983 to 2010, 86 patients with locally recurrent (n = 73, 85%) or primary advanced (n = 13, 15%) cervical cancer received IOERT following surgery. Common surgeries included pelvic exenteration (n = 26; 30%) or sidewall resection (n = 22; 26%). The median IOERT dose was 15 Gy (range, 6.25-25 Gy). Sixty-one patients (71%) received perioperative external beam radiotherapy (EBRT; median dose, 45 Gy). Forty-one patients (48%) received perioperative chemotherapy.

Results

Median follow-up was 2.7 years (range, 0.1-25.5 years). Resections were classified as R0 (n = 35, 41%), R1 (n = 30, 35%), or R2 (n = 21, 24%). Cumulative incidences of central (within the IOERT field) and locoregional relapse at 3 years were 23 and 38%, respectively. The 3-year cumulative incidence of distant relapse was 43%. Median survival was 15 months, and 3-year Kaplan-Meier estimates of cause-specific (CSS) and overall survival (OS) were 31 and 25%, respectively. On multivariate analysis, pelvic exenteration (p = 0.02) and perioperative EBRT (p = 0.009) were associated with improved central control in patients with recurrent disease. Recurrence within 6 months of initial therapy was associated with reduced CSS (p = 0.001). Common IOERT-related toxicities included peripheral neuropathy (n = 16), ureteral stenosis (n = 4), and bowel fistula/perforation (n = 4). Eleven of 16 patients with neuropathy required long-term pain medication.

Conclusions

Long-term survival is possible with combined modality therapy including IOERT for advanced cervical cancer. Distant relapse is common, yet a significant number of patients experienced local progression in spite of aggressive treatment. In addition to consideration of disease- and treatment-related morbidity, other factors to be considered when selecting patients for this approach include the time interval from initial therapy to recurrence and whether the patient is able to receive perioperative EBRT and pelvic exenteration in addition to IOERT.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10-29. 10.3322/caac.20138CrossRefPubMed
2.
Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49: 33-64. 10.3322/canjclin.49.1.33CrossRefPubMed
3.
Chen Y, Xu H, Li Y, Wang D, Li J, Yuan J: The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol 2008, 15: 2847-2855. 10.1245/s10434-008-0063-3CrossRefPubMed
4.
Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol 2004, 22: 872-880. 10.1200/JCO.2004.07.197CrossRefPubMed
5.
Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S: Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007, 68: 1081-1087. 10.1016/j.ijrobp.2007.01.026CrossRefPubMed
6.
Ijaz T, Eifel PJ, Burke T, Oswald MJ: Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol 1998, 70: 241-246. 10.1006/gyno.1998.5093CrossRefPubMed
7.
Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JM Jr: Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989, 73: 1027-1034. 10.1097/00006250-198906000-00024PubMed
8.
Webb MJ, Symmonds RE: Site of recurrence of cervical cancer after radical hysterectomy. Am J Obstet Gynecol 1980, 138: 813-817.PubMed
9.
Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone JM Jr, Edwards CL: Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988, 30: 381-387. 10.1016/0090-8258(88)90252-1CrossRefPubMed
10.
Friedlander M, Grogan M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002, 7: 342-347.PubMed
11.
Brady LW, Perez CA, Bedwinek JM: Failure patterns in gynecologic cancer. Int J Radiat Oncol Biol Phys 1986, 12: 549-557. 10.1016/0360-3016(86)90062-3CrossRefPubMed
12.
Perez CA, Fox S, Lockett MA, Grigsby PW, Camel HM, Galakatos A: Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods. Int J Radiat Oncol Biol Phys 1991, 21: 885-898. 10.1016/0360-3016(91)90726-KCrossRefPubMed
13.
Hanks GE, Herring DF, Kramer S: Patterns of care outcome studies. Results of the national practice in cancer of the cervix. Cancer 1983, 51: 959-967. 10.1002/1097-0142(19830301)51:5<959::AID-CNCR2820510533>3.0.CO;2-KCrossRefPubMed
14.
del Carmen MG, McIntyre JF, Fuller AF, Nikrui N, Goodman A: Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases. Gynecol Oncol 2000, 79: 457-462. 10.1006/gyno.2000.6002CrossRefPubMed
15.
Garton GR, Gunderson LL, Webb MJ, Wilson TO, Cha SS, Podratz KC: Intraoperative radiation therapy in gynecologic cancer: update of the experience at a single institution. Int J Radiat Oncol Biol Phys 1997, 37: 839-843. 10.1016/S0360-3016(96)00546-9CrossRefPubMed
16.
Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys 2001, 50: 687-694. 10.1016/S0360-3016(01)01507-3CrossRefPubMed
17.
Gerard JP, Dargent D, Raudrant D, Braillon G, Gilly FN, Romestaing P: Role of peroperative radiotherapy in the treatment of uterine cancers. Preliminary experience in Lyon. Bull Cancer Radiother 1994, 81: 186-195.PubMed
18.
Hicks ML, Piver MS, Mas E, Hempling RE, McAuley M, Walsh DL: Intraoperative orthovoltage radiation therapy in the treatment of recurrent gynecologic malignancies. Am J Clin Oncol 1993, 16: 497-500. 10.1097/00000421-199312000-00008CrossRefPubMed
19.
Mahe MA, Gerard JP, Dubois JB, Roussel A, Bussieres E, Delannes M: Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients. Int J Radiat Oncol Biol Phys 1996, 34: 21-26. 10.1016/0360-3016(95)02089-6CrossRefPubMed
20.
Martinez-Monge R, Jurado M, Aristu JJ, Moreno M, Cambeiro M, Perez-Ochoa A: Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer. Gynecol Oncol 2001, 82: 538-543. 10.1006/gyno.2001.6329CrossRefPubMed
21.
Roth TM, Secord AA, Havrilesky LJ, Jones E, Clarke-Pearson DL: High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease. Gynecol Oncol 2003, 91: 258-260. 10.1016/S0090-8258(03)00443-8CrossRefPubMed
22.
Tran PT, Su Z, Hara W, Husain A, Teng N, Kapp DS: Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007, 69: 504-511. 10.1016/j.ijrobp.2007.03.021CrossRefPubMed
23.
Stelzer KJ, Koh WJ, Greer BE, Cain JM, Tamimi HK, Figge DC: The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity. Am J Obstet Gynecol 1995, 172: 1881-1886. 10.1016/0002-9378(95)91427-7CrossRefPubMed
24.
Konski A, Neisler J, Phibbs G, Bronn D, Dobelbower RR Jr: The use of intraoperative electron beam radiation therapy in the treatment of para-aortic metastases from gynecologic tumors: a pilot study. Am J Clin Oncol 1993, 16: 67-71. 10.1097/00000421-199302000-00017CrossRefPubMed
25.
Gunderson LL, Nelson H, Martenson JA, Cha S, Haddock M, Devine R: Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Dis Colon Rectum 1996, 39: 1379-1395. 10.1007/BF02054527CrossRefPubMed
26.
Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH: Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60: 249-257. 10.1016/j.ijrobp.2004.02.044CrossRefPubMed
27.
Maneo A, Landoni F, Cormio G, Colombo A, Mangioni C: Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer 1999, 9: 295-301. 10.1046/j.1525-1438.1999.99037.xCrossRefPubMed
28.
Haasbeek CJ, Uitterhoeve AL, van der Velden J, Gonzalez DG, Stalpers LJ: Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 2008, 89: 197-204. 10.1016/j.radonc.2008.01.004CrossRefPubMed
29.
Andikyan V, Khoury-Collado F, Gerst SR, Talukdar S, Bochner BH, Sandhu JS: Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome. Gynecol Oncol 2012, 126: 346-350. 10.1016/j.ygyno.2012.04.034CrossRefPubMed
30.
Baiocchi G, Guimaraes GC, Rosa Oliviera RA, Kumagai LY, Faloppa CC, Aguiar S: Prognostic factors in pelvic exenteration for gynecological malignancies. Eur J Surg Oncol 2012, 38: 348-354.CrossRef
31.
Benn T, Brooks RA, Zhang Q, Powell MA, Thaker PH, Mutch DG: Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecol Oncol 2011, 122: 14-18. 10.1016/j.ygyno.2011.03.003CrossRefPubMed
32.
de Wilt JH, van Leeuwen DH, Logmans A, Verhoef C, Kirkels WJ, Vermaas M: Pelvic exenteration for primary and recurrent gynaeological malignancies. Eur J Obstet Gynecol Reprod Biol 2007, 134: 243-248. 10.1016/j.ejogrb.2006.07.025CrossRefPubMed
33.
Kadar N: Port-site recurrences following laparoscopic operations for gynaecological malignancies. Br J Obstet Gynaecol 1997, 104: 1308-1313. 10.1111/j.1471-0528.1997.tb10980.xCrossRefPubMed
34.
West CM, Davidson SE, Burt PA, Hunter RD: The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. Int J Radiat Oncol Biol Phys 1995, 31: 841-846. 10.1016/0360-3016(94)00508-7CrossRefPubMed
Metadata
Title
Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer
Authors
Brandon M Barney
Ivy A Petersen
Sean C Dowdy
Jamie N Bakkum-Gamez
Kristi A Klein
Michael G Haddock
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-80

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case

Research

Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease

Research

Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction

Research

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume

Research

Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control

Research

Palliative radiotherapy in patients with a poor performance status: the palliative effect is correlated with prolongation of the survival time